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Abstract
We have characterized a novel 21 amino acid-peptide derived from AntrumMucosal Protein
(AMP)-18 that mediates growth promotion of cultured normal epithelial cells and mitigates
radiation-induced oral mucositis in animal models, while suppressing in vitro function of
cancer cells. The objective of this study was to evaluate these dual potential therapeutic
effects of AMP peptide in a clinically relevant animal model of head and neck cancer (HNC)
by simultaneously assessing its effect on tumor growth and radiation-induced oral mucositis
in an orthotopic model of HNC. Bioluminescent SCC-25 HNC cells were injected into the
anterior tongue and tumors that formed were then subjected to focal radiation treatment.
Tumor size was assessed using an in vivo imaging system, and the extent of oral mucositis
was compared between animals treated with AMP peptide or vehicle (controls). Synergism
between AMP peptide and radiation therapy was suggested by the finding that tumors in the
AMP peptide/radiation therapy cohort demonstrated inhibited growth vs. radiation therapy-
only treated tumors, while AMP peptide-treatment delayed the onset and reduced the sever-
ity of radiation therapy-induced oral mucositis. A differential effect on apoptosis appears to
be one mechanism by which AMP-18 can stimulate growth and repair of injured mucosal
epithelial cells while inhibiting proliferation of HNC cells. RNA microarray analysis identified
pathways that are differentially targeted by AMP-18 in HNC vs. nontransformed cells.
These observations confirm the notion that normal cells and tumor cells may respond differ-
ently to common biological stimuli, and that leveraging this finding in the case of AMP-18
may provide a clinically relevant opportunity.
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Introduction
Despite its frequency, severity and symptomatic and economic impact, there is no effective
intervention for oral mucositis (OM) induced by chemotherapeutic or radiation regimens
(CRT) used to treat head and neck cancers (HNC) [1–4]. Clinically, OM is characterized by
mucosal breakdown resulting in extensive, deep ulcerations, severe function-altering pain,
increased risk of secondary infection, bacteremia and sepsis, and expanded need for gastro-
stomy feedings, and ambulatory and in-patient supportive care. Virtually all patients who
receive CRT for the treatment of HNC develop at least moderate OM; more than two-thirds
suffer from severe forms of the condition.
Current standard therapy for mucositis is predominantly palliative while focused on pain
control and maintenance of nutrition. The only approved treatment for mucositis thus far is
palifermin (Kepivance1), and its application is limited to mucositis in patients undergoing
conditioning regimens prior to hematopoietic stem cell transplant [5].
The complexity of mucositis as a biological process has only been appreciated recently [6–
8]. It has been suggested that the condition represents a sequential interaction of oral mucosal
cells and tissues, reactive oxygen species, pro-inflammatory cytokines, mediators of apoptosis,
and local factors such as saliva and the oral microbiota. It appears that the early changes associ-
ated with radiation-induced mucosal toxicity occur within the endothelium, and connective
tissue of the submucosa [6]. This ultimately results in damage and disruption of the epithelial
barrier, the most critical step in the development of mucositis. Epithelial barrier function
largely depends on the intercellular junctions at the apical-most domains of the plasma mem-
brane, i.e., the tight junctions (TJs) that regulate paracellular permeability across the epithelium
in monolayer cell cultures and in vivo [9].
We have identified and characterized a novel 21-amino acid peptide derived from amino
acids 77–97 of AntrumMucosal Protein (AMP)-18, also known as gastrokine-1 (GKN1) [10–
12], that was initially discovered in epithelial cells of the gastric mucosa [10]. Both AMP-18
and the peptide protect against and speed recovery from mucosal injury in animal models of
OM induced by radiation and/or chemotherapy as used to treat patients with HNC [13, 14].
The peptide can be easily synthesized, and exhibits long-term stability. In a mouse model of
OM induced by a single dose of radiation to the snout, AMP peptide administered once daily
four days before radiation and continued 10 days afterwards effectively prevented the complete
loss of tongue epithelium observed in irradiated mice given vehicle (saline) [13]. In established
hamster OMmodels induced by a single dose of radiation, fractionated radiation, or fraction-
ated radiation together with cisplatin to simulate conventional treatments of HNC, daily sub-
cutaneous administration of AMP peptide delayed the onset of mucosal erythema, reduced the
severity of ulceration and accelerated oral mucosal recovery in all three models, likely in part
by its anti-apoptotic effects seen in cultures of epithelial and endothelial cells [14].
In contrast to other currently trialed or symptom-relieving agents now in use to treat oral
mucositis, AMP peptide and recombinant human (rh) AMP-18 appear to uniquely target TJs
that connect adjacent epithelial cells by increasing accumulation of TJ proteins, limiting their
loss during injury, and facilitating formation of new TJs following mucosal barrier injury [12,
15]. This TJ-enhancing effect is closely associated with rearrangement of perijunctional actin
and formation of ‘‘polarity protein” complexes. AMP-18 appears to achieve its therapeutic
effects by binding to the gastrin/cholecystokinin B receptor (CCKBR) and activating multiple
signaling pathways such as MAPKs, PI3K/AKT, RhoA, and PKCz [13, 15, 16].
To continue development of AMP peptide as an effective and safe therapeutic agent, its
effects on growth of cancer cells in the setting of radiation therapy protocols in vivo were stud-
ied in a xenograft model using inoculated human carcinoma cells to generate tumors in nude
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rats [14]. We reported that focal radiation treatment significantly reduced tumor volume as
expected. Unexpectedly, administration of AMP peptide significantly added to radiation-
induced growth inhibition, demonstrating the tumor suppressor property of AMP-18 we and
others observed previously [11, 17, 18]. Together these findings suggested that AMP peptide
treatment of OM would not interfere with the therapeutic effects of radiation protocols in the
treatment of head and neck tumors, or promote growth of cancer cells, but could instead sensi-
tize tumor cells to radiation.
In this study we set out to determine if AMP-18 could sensitize HNC cells to chemothera-
peutic agents, and also demonstrate in the same animal, beneficial effects of oral mucosal pro-
tection along with suppression of tumor cell growth following radiotherapy.
Materials and Methods
Materials
Chemically synthesized AMP peptide (LDALVKEKKLQGKGPGGPPPK), a scrambled peptide
(GKPLGQPGKVPKLDGKEPLAK), and recombinant human (rh)AMP-18 were prepared by
GenScript (Piscataway, NJ) as described previously [13]. Briefly, rhAMP-18 is expressed and
purified as a His6-tagged fusion protein. The coding sequence for full-length human AMP-18
was cloned into an E. coli expression vector, pGSE3, and the expressed protein was purified
from 5 L of culture medium by affinity column chromatography. AMP peptide and rhAMP-18
were found to be equally effective in triggering cellular responses as previously reported [13–
15]. Cell culture medium, fetal bovine serum (FBS), penicillin and streptomycin were obtained
from Gibco BRL, Life Technologies (Gaithersburg, MD). Tumor necrosis factor (TNF)-α was
purchased from PeproTech (Rocky Hill, NJ), and other reagents from Sigma-Aldrich unless
otherwise specified.
Cell Cultures
To investigate the effects of treatment with AMP peptide or AMP-18 in cancer cells exposed to
cisplatin, two established human HNC cell lines that were shown in preliminary studies to
exhibit differential sensitivity to cisplatin were used: SCC-25 (American Type Culture Collec-
tion, ATCC CRL1628) (Manassas, VA) which is more sensitive than SCC-61 [19]. The SCC-25
cell line has been maintained in the authors’ lab for 3 years; SCC-61 cells were established and
authenticated by Weichselbaum et al. [20–22], received as a gift, and maintained for 4 years.
Cells were grown in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F12
medium containing 1.2 g/L sodium bicarbonate, 2.5 mM L-glutamine, 15 mMHEPES and 0.5
mM sodium pyruvate, and supplemented with 400 ng/ml hydrocortisone, 10% FBS, penicillin
(50 U/mL) and streptomycin (50 μg/mL), at 37°C in a humidified incubator supplemented
with 5% CO2. SCC-25 and SCC-61 cells (2 × 10
3 /well) were grown on 96-well plates for 24 h
in medium containing 1% FBS, and were then left untreated, exposed to cisplatin only (2 μM
for SCC-25 cells, 10 μM for SCC-61 cells), cisplatin in the presence of 2 μg/ml AMP peptide, or
rhAMP-18 (dissolved in phosphate buffered saline, PBS, vehicle) for 48 h. Cell viability was
assayed by CellTiter-Blue reagent using a microplate reader (Bio-Tek, Winooski, VT). Experi-
ments were performed in quadruplicate. Human, adult, (low concentration of) Calcium, ele-
vated Temperature (HaCaT) skin keratinocytes, a nontransformed cell line used to model
normal stratified squamous epithelium of the oral mucosa [23], were obtained from Thermo
Fisher Scientific (Waltham, MA) and maintained in Dulbecco's modified Eagle's medium with
FBS, penicillin and streptomycin as described [13] for 5 years. Oral TERT-2 immortalized ker-
atinocytes were considered as a cell model to compare to oral cancer [24], but the HaCaT cell
line was chosen because it has been more widely used for this purpose.
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Creation of Orthotopic Model of HNC in Nude Mice
To study possible synergistic effects of AMP peptide on limiting cancer cell growth while protect-
ing against OM in the same animal, an orthotopic model of HNC was used. Tumors in the ton-
gue were generated, their size was assessed using an in vivo imaging system (IVIS), and the extent
of radiation-induced OMwas compared between animals treated with AMP peptide or vehicle
(controls). Animal use was approved by Biomodels’ Institutional Animal Care and Use Commit-
tee (12-1016-01). The Office of Laboratory Animal Welfare assurance number is A4591-01.
Based on preliminary in vivo studies, SCC-25 cells were labeled with a lentiviral dual biolumi-
nescent and fluorescent imaging vector UBC-GFP-T2A-Luciferase (LUC) (System Biosciences,
Inc., Mountain View, CA), and injected into the anterior tongue to form tumors. These biolumines-
cent SCC-25 cells, referred to as SCC-25-LUC, enable in vitro selection of positive cells by flow
cytometric sorting using green fluorescent protein (GFP) and non-invasive monitoring of cellular
dynamics utilizing an in vivo imaging system (IVIS) (Perkin Elmer) to measure tumor size. SCC-
25-LUC cells were sorted 3 times by BD FACSAria (BD Biosciences) so that GFP-positive cells
were>95% (data not shown). The sensitivity and accuracy of in vitro and in vivo cell monitoring
offers several advantages over traditional methods that require sacrificing animals and histological
analysis. In addition, histopathological correlates of the clinical changes assessed in the model have
been extensively documented [13, 25], so that histology was not a part of the current study.
Athymic nude mice (Foxn1nu) (age 6 to 8 weeks, body weight 29.5 ± 2.0 g) were purchased
from Charles River Laboratories. Mice were anesthetized with isoflurane and 1 x 106 SCC-
25-LUC cells suspended in 30 μL 1x HBSS were injected directly into the anterior tongue using
a 0.1 mL tuberculin syringe with a 30 gauge needle, as described by Myers et al. [26]. After 21
days to permit tumor growth, a total of 32 mice were randomized into 4 groups (8 mice/group)
based on a quantitative assessment of tumor size as determined by total flux from each tumor
measured by IVIS imaging [27].
The day of randomization was designated Day 0. Animals in Group 1 were not treated,
Group 2 mice received vehicle (PBS), and Groups 3 and 4 received AMP peptide at a dose of 25
mg/kg once daily via subcutaneous (s.c.) injection. On study Day 4, animals in Groups 2 and 4
were given a single acute dose of 30 Gy of radiation directed to the tongue to treat the tumors
and induce OM. The model isolates the target tissue (tongue) with a lead shield, thereby avoid-
ing systemic toxicity. Following administration of anesthesia, mice were radiated with using a
160 kilovolt potential (18.75-ma) source at a focal distance of 15 cm, hardened with a 3.0 mm
Al filtration system. Treatment with AMP peptide or vehicle was continued for 14 days.
Animals were anesthetized, their tongues gently extruded using a forceps and photographs
were obtained to document tumor progression. Tumor growth was assessed and compared on
Days 5, 8, 10 and 14 using IVIS after injection of D-luciferin. After photographs were taken,
OM was scored clinically, and animals were imaged using the IVIS system. Prior to imaging,
mice were injected with 0.1 mL / 20 g body weight of 15 mg/mL D-luciferin-K+ bioluminescent
substrate in PBS. Ten minutes following injection, mice were anesthetized and placed in the
IVIS1 Lumina at maximum sensitivity for up to 5 minutes exposure to detect biolumines-
cence with an open emission filter. Saved images were loaded into Living Image1 analysis
software and color scales were matched based on maximum and minimum radiance (photons/
second/cm2/steradian). Identical regions of interest were drawn for each animal and total flux
was determined in terms of photons/second for each region of interest.
Oral Mucositis
The onset and progression of OM was scored clinically using a well-established six point scale:
Grade 0, no abnormalities. Grade 1, slight mucosal changes characterized by areas of mild
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erythema, mucosa intact. Grade 2, mild mucositis defined by areas of moderate to severe ery-
thema and superficial epithelial necrosis such that there may be mild sloughing, but the epithe-
lial base is intact. Grade 3, moderate mucositis characterized by frank ulcer formation. Ulcers
typically have areas of necrosis with associated yellowish/gray coloration with pseudomem-
brane formation. Cumulative area of ulceration 25% of tongue surface area. Grade 4, severe
mucositis with ulcer formation affecting 25% to 50% of tongue mucosa. Marked erythema and
pseudomembrane formation. Loss of pliability. Grade 5, severe mucositis ulcer formation of
virtually all mucosa areas at risk. Loss of mobility and pliability [25, 28, 29]. Scores of 1 and 2
indicate mild stages of mucositis. Ulcerative mucositis is characteristic of grades 3–5 with
grades 3 and 4 representing severe stages of the condition. Representative images of this scale
are defined in Fig 1. Following visual clinical scoring, a photograph was taken of each animal’s
oral mucosa using a standardized technique. At the conclusion of the experiment, photographs
were randomly numbered and scored by two independent, trained observers who graded the
images in blinded fashion using the above-described scale (blinded scoring). For each photo-
graph, the actual blinded score was based on the average of the 2 observers’ scores. Only scores
from the blinded, photographic evaluation were reported and used for statistical analyses.
Animals were weighed and monitored for general health daily. In addition to the standard
diet, all animals were given highly palatable soft food in their cages. Group weight change was
recorded as a mean percent weight change.
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis
(SDS-PAGE) and Immunoblotting Assay of Caspase 3 Cleavage
To determine the role of apoptosis as a conduit for disparate AMP-18 effects on normal epithe-
lial and HNC cancer cells, caspase 3 cleavage was used as an index of cell apoptosis and com-
pared in nontransformed HaCaT and HNC SCC-25 cells exposed to TNF-α using
immunoblotting. To prepare cell lysates, cultures were rinsed and then harvested in iced PBS
Fig 1. Mucositis Scoring Scale. Representative images of radiation-induced mucositis used for scoring are
shown. See details in the Methods.
doi:10.1371/journal.pone.0152995.g001
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by scraping the monolayer with a cell lifter. The detached cells were pelleted at 4°C and
extracted on ice for 30 min in lysis buffer (50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 0.25%
sodium deoxycholate, 150 mM NaCl, 100 mMNaF, 10% glycerol, 10 mM EDTA) containing
protease and phosphatase inhibitors (2 mM sodium orthovanadate, 1 mM phenylmethylsulfo-
nyl fluoride, 50 μg/mL antipain, 1 μg/mL aprotinin, 1 μg/mL leupeptin, and 1 μg/mL pepsta-
tin). Cell lysates were clarified by centrifugation at 14000 × g for 15 min at 4°C. Protein
concentration was determined by BCA assay (Pierce).
For immunoblotting assays, 30 to 50 μg protein/lane was resolved by SDS-PAGE, transferred
onto Immobilon membranes (Millipore, Bedford, MA) followed by blocking with 5% bovine
serum albumin in TBST (20 mM Tris-HCl, 150 mMNaCl, 0.1% Tween 20 at pH 7.5), and incu-
bated with designated antibodies. After incubation with horseradish peroxidase (HRP)-conju-
gated secondary antibodies, immunoreactive bands were visualized using chemiluminescence
(ECL, Amersham Biosciences). When reprobed, blots were first stripped with a buffer containing
50 mMTris-HCl, pH 6.8, 2% SDS, and 0.1 M 2-mercaptoethanol. Images were analyzed by den-
sitometry. The immunoblots shown in the figure represent one of at least three experiments.
RNAMicroarray Analysis Comparing Nontransformed and HNC Cells
Treated with AMP-18
To define the differential biological impact and relevance of AMP-18 on normal and tumor tis-
sue, and to identify putative pathway gene targets that could mediate the dual therapeutic
effects we compared its effect on gene expression of cultured nontransformed (HaCaT) or
squamous cell carcinoma cells treated with AMP-18.
We [13, 14] and others [30–34] have utilized the human immortalized nontransformed skin
keratinocyte HaCaT line [23] to model the oral mucosal epithelium and for comparison with
squamous head and neck cancer cells, whereas immortalized oral TERT-2 keratinocytes have
been used less often to model oral mucositis.
Total RNA was extracted from SCC-61 and HaCaT cells, with or without AMP-18 treat-
ment, using the RNeasy kit (Quiagen) according to the manufacturer’s specifications. RNA
integrity and concentration were assessed using an Agilent Bioanalyzer 2100. Total RNA was
processed into biotinylated cRNA using the Illumina1 TotalPrep™-96 RNA Amplification Kit
(Ambion, cat no: 4393543). The cRNA was hybridized to Illumina HumanHT12v4 arrays
using Illumina provided protocols and scanned using an Illumina HiScan in the University of
Chicago Genomics Core laboratories.
Using microarray data from HaCaT and SCC-61 cells obtained at 2 hours and 24 hours after
exposure to AMP-18 (and no treatment controls), we used an approach that optimized an initial
supervised component with subsequent statistically driven hierarchical ranking. Genes which
were most discriminatory between the two groups were ranked according to their discriminatory
value as defined by their Fisher’s ratio in which the predictive accuracy of the different ordered
reduced sets were determined using a backward recursive feature elimination algorithm. This
procedure eliminated redundant or irrelevant genes to yield the most precise set of genes with
the greatest predictive value. We then evaluated the most differentially expressed genes for dis-
ease attribution, pathway association, and gene ontology using GeneAnalytics software and tested
functional/phenotypic associations using VarElect [8, 35, 36]. The top 20 genes differentially
expressed in SCC-61 and HaCaT cells treated with AMP-18 for 2 h are shown in S1 Table.
Statistical Analyses
Mucositis was scored using the blinded photographs, beginning on Day 4, and for every day
thereafter. Statistical differences between treatment groups were determined using the Mann-
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Whitney Rank Sum test and chi-square analysis with a critical value of 0.05. The effect of drug
treatment on mucositis compared to vehicle control was assessed according to the following
parameters: 1. The difference in the number of days mice in each group had severe mucositis
(score 3) was analyzed. On each day the animals were scored (evaluation day), the number
of animals with a blinded mucositis score of 3 in each treatment group was compared to the
vehicle group. Differences were analyzed on a daily as well as a cumulative basis. Treatment
success was determined by a statistically significant lower number of mice with this score in a
drug treatment group, versus vehicle, as determined by chi-square analysis. 2. The rank sum
differences in daily mucositis scores in treatment groups versus the vehicle group were deter-
mined. For each evaluation day the scores of the vehicle group were compared to that of the
treated groups using non-parametric rank sum analysis. Treatment success was determined by
a statistically significant lowering of scores in the treated group on two or more days from Day
4 to Day 14. A one-way ANOVA or ANOVA on ranks was used to evaluate the area-under the
curve for animal weights and IVIS measurements. Data were analyzed with Minitab software
(Minitab, State College, PA). Groups were compared by two-tailed t test or, for more than two
groups, by analysis of variance. We considered P 0.05 significant.
Results
Inhibitory Effects of AMP Peptide and rhAMP-18 on HNC Cells
To investigate the effects of AMP peptide or AMP-18 on HNC cells in culture, human head
and neck squamous cell carcinoma SCC-25 (Fig 2, panel A) and SCC-61 (panel B) cells were
left untreated, exposed to AMP-18 (2 μg/ml), cisplatin (2 μM for SCC-25 cells, 10 μM for SCC-
61 cells) only, cisplatin in the presence or absence of AMP peptide or rhAMP-18. Cell viability
Fig 2. Inhibitory effects of AMP peptide and AMP-18 on HNC cells. SCC-25 (A) or SCC-61 (B) cells were
left untreated, exposed to AMP-18 (2 μg/ml), cisplatin (2 μM for SCC-25 cells, 10 μM for SCC-61 cells) only,
cisplatin in the presence of 2 μg/ml AMP peptide, or rhAMP-18 for 48 h. Cell viability was assayed by
CellTiter-Blue reagent. Experiments were performed in quadruplicate. Values are mean ± SE. Adding either
AMP peptide or rhAMP-18 amplified the cytotoxicity of cisplatin by inhibiting growth of SCC-25 cells by >30%
(AMP peptide, P = 0.013; rhAMP-18, P = 0.03), and SCC-61 cells by 65% (P<0.05) and 75% (P<0.02),
respectively.
doi:10.1371/journal.pone.0152995.g002
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was assessed with the CellTiter-Blue1 Cell Viability Assay reagents (Promega) using a micro-
plate reader. AMP-18 alone inhibited growth of SCC-25 (P = 0.02) and SCC-61 (P = 0.04) cells
by 10–15% (Fig 2). Cisplatin significantly inhibited growth of both cell lines: SCC-25 cells by
25%, and SCC-61 cells by 50% compared to control cultures (P<0.001). Adding either AMP
peptide or rhAMP-18 amplified the cytotoxicity of cisplatin by inhibiting growth of SCC-25
cells by>30% (AMP peptide, P = 0.013; rhAMP-18, P = 0.03), and SCC-61 cells by 65%
(P<0.05) and 75% (P<0.02), respectively.
AMP Peptide Treatment Additively Inhibits Cancer Growth with
Radiation
Previous evidence that AMP peptide could sensitize cancer cells to radiation in a xenograft
model [14] and two human HNC cell lines to cisplatin in culture (Fig 2), together with our
studies in mice and hamsters that treatment with the peptide had beneficial clinical effects in
radiation- and cisplatin-induced OM [13, 14], led us to ask if these dual effects of AMP peptide
could be demonstrated in an orthotopic model of HNC in the same animal. Four groups of ani-
mals were studied: 1. untreated; 2. PBS (vehicle) and radiation; 3. AMP peptide; and 4. AMP
peptide and radiation.
To determine the impact of treatment with AMP peptide on tumor progression with and
without radiation therapy, the tumors of all animals were assessed using the IVIS system. In
non-irradiated mice, the orthotopic tumors in the tongue grew progressively, and administra-
tion of AMP peptide did not change tumor size significantly (Groups 1 and 3) (Fig 3). On Days
5 and 8 IVIS values for untreated (6.59×107 ± 9.6×106) and AMP peptide treated (6.50×107 ±
8.67×106) were not statistically different, as was also the case on Days 10 and 14 when IVIS val-
ues for untreated (1.78×108 ± 2.47×107) and AMP peptide treated (1.61×108 ± 2.32×107) did
not differ. In mice given radiation (30 Gy), tumor size, measured as mean IVIS radiance, con-
tinued to grow with PBS (vehicle) treatment (Group 2), but remained unchanged with AMP
peptide treatment between Days 5 and 8 and Days 10 and 14 (Group 4) (Fig 4). Tumor size
(means ± SE) in radiated mice, given AMP peptide compared to mice given PBS, was signifi-
cantly reduced (P = 0.03) when assessed on Days 10 and 14 (Fig 4). This observation suggested
that AMP peptide did not interfere with the ability of focused radiation to inhibit cell growth,
but rather halted growth of cancer cells.
AMP peptide did not exhibit any adverse effects on body weight. Mice in all 4 groups exhib-
ited weight loss after tumors were established in the tongue which was more marked in irradi-
ated animals (data not shown).
Therapeutic Effects of AMP Peptide on Radiation-Induced Oral
Mucositis
In agreement with the results of previous studies, AMP peptide mitigated the development oral
mucositis induced by radiation [14]. While radiated control (PBS) animals all developed ulcer-
ative mucositis (Group 2) by day 12, only 37.5% of AMP-treated animals (Group 4) were so
affected (P = 0.03), whereas on day 11, mucosal ulceration appeared in 62.5% in Group 2, but
none given AMP peptide (P = 0.003) (Fig 5). Thus, AMP peptide delayed the onset of ulcerative
mucositis and favorably impacted its duration.
AMP-18 Inhibited Apoptosis in HaCaT but Not in HNC Cells
Recent results from our studies [10–15] and others [17] suggest that AMP-18 has pleiotropic
effects. AMP-18 stimulates growth and is anti-apoptotic in epithelial cells including HaCaT
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Fig 3. Effect of AMP peptide and radiation treatment in an orthotopic model of HNC cancer in the
tongue assessed using IVIS. An orthotopic model of HNC cancer was established by inoculating
bioluminescent SCC-25-LUC cells into the anterior tongue of nude mice. Tumor size in different groups was
assessed and compared on Days 5 and 8 as well as Days 10 and 14 using IVIS after injection of D-luciferin.
Mice in Group 1 and Group 3 were not irradiated, whereas animals in Groups 2 and 4 received 30 Gy on Day
0 of the study. Treatment with PBS (Group 2) or AMP peptide (Group 4) was administered by injection s. c.
once daily. In the irradiated mice, treatment with AMP peptide was associated with much lower IVIS radiance
compared to treatment with PBS, indicating that AMP peptide reduced tumor growth. Representative IVIS
images of tongue tumors from 32 mice are shown.
doi:10.1371/journal.pone.0152995.g003
Fig 4. Effect of AMP peptide and radiation treatment of HNC tumors in the anterior tongue of nude
mice with time assessed by measuring tumor IVIS radiance. Irradiated animals were treated with AMP
peptide or PBS, and IVIS radiance was measured on Days 5 and 8, and then on Days 10 and 14. Means ± SE
were compared. In mice given PBS, IVIS radiance appeared to increase between Days 5 and 8 and 10 and
14, whereas radiance in animals treated with AMP peptide was unchanged between Days 5 to 14. On Days
10 and 14, treatment with AMP peptide significantly reduced tumor size compared to treatment with PBS (*
P = 0.03). In non-irradiated mice, the orthotopic tumors in the tongue grew progressively; administration of
AMP peptide did not change tumor size significantly (not shown).
doi:10.1371/journal.pone.0152995.g004
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keratinocytes [13]. It also appears to function as a tumor suppressor [37], possibly by inducing
apoptosis [38], inhibiting the epithelial–mesenchymal transition (EMT) and cancer cell migra-
tion [39], and/or inducing cellular senescence [40]. Indeed, expression of AMP-18 is downre-
gulated or absent in gastric cancer tissue [11, 17, 18], and decreases as chronic gastritis
progresses to atrophy and metaplasia [40, 41].
To determine if apoptosis could be a mechanism by which AMP-18 exerts its dual effects on
normal epithelial and HNC cancer cells observed in the orthotopic model, the effect of AMP-
18 on caspase 3 cleavage as an index of cell apoptosis was compared in nontransformed
HaCaT and HNC SCC-25 cells exposed to TNF-α, a proinflammatory cytokine known to
mediate chemo- and radiation-therapy induced injury of the oral mucosa.
Minimal apoptosis was observed in both cell lines under control conditions whereas expo-
sure to TNF-α induced a significant increase in cleaved caspase 3 (Fig 6); 8.1-fold in HaCaT,
and 2.8-fold in SCC-25 cells. However, in HaCaT cells treated with AMP-18, caspase 3 cleavage
was inhibited by 50–75% (P = 0.02), suggesting an anti-apoptotic effect of AMP-18. In contrast,
treatment of SCC-25 cells with AMP-18 did not inhibit TNF-α induced cleavage of caspase 3
in SCC-25 cells, indicating a different response in these cancer cells.
Pathways differentially targeted by AMP-18 in SCC-61 and HaCaT cells
As SCC-61 cells were found to be more sensitive than SCC-25 cells to the additive inhibitory
effects of AMP-18/peptide with cisplatin on cell viability (Fig 2), SCC-61 cells were chosen for
microarray analysis. Consistent with the different effects of AMP-18 noted in the tumor
modeling component of the study (Figs 4 and 5), a differential impact of AMP-18 on HaCaT
(nontransformed immortalized skin keratinocytes) vs. SCC-61 (HNC) cells was also seen using
microarray analysis (GEO number: GSE73330).
As expected, assessment of baseline gene expression of SCC-61 cells identified genes associ-
ated with head and neck squamous cell carcinoma and tongue squamous cell carcinoma. Anal-
ysis of pathways associated with AMP-18 treatment (at 2 hours) of SCC-61 cells vs. AMP-
naïve SCC-61 cells, suggested that AMP-18 initiated differential gene expression associated
with pathways functionally related to cell metabolism, oxidation, and tumor behavior (Table 1,
left column).
Fig 5. Mean daily mucositis scores in irradiatedmice. Irradiation of the tongue and oral mucosa was
followed by daily treatment with AMP peptide or vehicle (PBS). Ulcerative oral mucositis that developed was
scored as described inMethods. A mucositis score of 3.0 (broken line) indicates mucosal ulceration that
correlates with significant human oral mucositis. Animals treated with the vehicle reached a score of 3 on Day
12, whereas mice treated with AMP peptide did not. Mucositis score was significantly lower on Days 11 (*
P = 0.003) and 12 (** P = 0.03), but not Day 13 (P = 0.1) in animals treated with AMP peptide compared to
those given the vehicle. Values are means ± SE.
doi:10.1371/journal.pone.0152995.g005
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HaCaT cells exposed to AMP-18 for 2 hours resulted in an entirely different set of expressed
genes, as indicated by their functional relationships (Table 1,middle column). To better under-
stand the differential effects of AMP-18 on normal (HaCaT) and tumor (SCC-61) cells, we
assessed the functional significance of differentially expressed genes after a 2 hour exposure to
AMP-18. In contrast to the pathways noted when only SCC-61 cell gene expression was stud-
ied, we noted a high prevalence of functions associated with pathways typically correlated with
tumor behavior. In particular, a number of pathways identified are strongly associated with
local tumor spread and invasion characteristics (Table 1, right column).
Discussion
We have characterized a novel peptide derived from AntrumMucosal Protein (AMP)-18 that
demonstrates pleiotropic effects including growth promotion, anti-apoptosis, and tight junc-
tion (TJ) enforcement in animal models of OM [13, 14]. In a xenograft model reported previ-
ously, AMP peptide sensitized human cancer cells to radiation therapy. In the present study,
we have extended this observation to cultured human HNC cells exposed to cisplatin and
treated with AMP peptide or full length AMP-18 protein (Fig 2). We also demonstrated in an
orthotopic mouse model of squamous cell cancer of the tongue that AMP peptide administered
together with radiation exerts both its radioprotective effects on the oral mucosa and tumor-
suppressing properties in the same animal (Figs 3–5). Differential effects of AMP-18 on apo-
ptosis in nontransformed compared to cancer cells suggest an underlying mechanism for the
dual effects (Fig 6). Consistent with our in vivo observations, we showed that AMP-18 differen-
tially impacted normal and HNC cell gene expression. Pathway attribution associated with
these differences was also consistent with phenotype. These results provide an experimental
rationale to develop AMP peptide as a therapeutic agent to protect against and speed healing in
patients with HNC who acquire chemotherapy and/or radiation-induced OM.
Epithelial cells comprise the most important layer of the mucosal barrier. Degeneration and
breakdown of the epithelium results in mucosal ulceration. Epithelial barrier function is
Fig 6. Differential effects of AMP-18 on cleavage of caspase 3 in HaCaT and SCC-25 cells.
Nontransformed human keratinocyte (HaCaT cells) and human HNC (SCC-25) cell cultures were each
exposed to TNF-α for 6 h to induce apoptosis displayed as increased cleavage of caspase 3; 8.1-fold in
HaCaT, and 2.8-fold in SCC-25 cells. Treatment with rhAMP-18 appeared to block TNF-α –induced cleavage
of caspase 3 in HaCaT (50–75%, * P = 0.02) but not in HNC cells. Each immunoblot represents one of three
experiments.
doi:10.1371/journal.pone.0152995.g006
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regulated by the TJs, a multiple protein complex linked to the cytoskeleton that regulates
mucosal permeability in both physiological and pathological states [42–44]. The importance of
TJs in the pathoetiology of regimen-related mucosal injury is becoming increasingly clear [45].
Thus targeting epithelial cells and TJs to treat OM seems a promising strategy. We have charac-
terized a novel peptide derived from AMP-18 that demonstrates pleiotropic effects that appear
to function differently than do other currently trialed or symptom-relieving agents. It is mito-
genic, anti-apoptotic and can stimulate formation of TJs in nontransformed epithelia, while
also possibly presensitizing transformed epithelial cells of head and neck cancers to apoptosis
(Fig 6). With these multiple roles, AMP-18 appears to maintain mucosal barrier function and
structure by adjusting cellular homeostatic balance between proliferation and apoptosis [46]
and regulating dynamics of TJs. The potent mucosal protective and healing effects of AMP
peptide have been observed in our previous studies using established OMmodels in mice and
hamsters [13, 14].
However, treatment with AMP peptide would be untenable if it caused growth of tumor
cells or inhibited the antineoplastic effects of radiation or chemotherapy. This concern was
proven to be untrue in a xenograft model [14]. Instead, subcutaneous administration of AMP
peptide significantly added to radiation-induced inhibition of cancer cell growth, demonstrat-
ing tumor suppressor property as we and others have observed [11, 17, 18]. Here we have
Table 1. Hierarchically arranged lists of pathways differentially targeted by AMP-18 in SCC-61 and HaCaT cells. SCC-61 and HaCaT cells were
treated with AMP-18 for 2 h, total RNA was purified and subjected to RNAmicroarray analysis. Differentially expressed pathways were identified as stated in
the Methods with no AMP-18 treatment as a control.
SCC-61 cells HaCaT cells HaCaT vs. SCC-61 cells
• Fatty acid biosynthesis • microRNAs in cardiomyocyte
hypertrophy
• Selenium pathway
• Validated targets of C-MYC transcriptional repression • (S)-reticuline biosynthesis II • Immune response IFNα/β signaling pathway
• Physiological and pathological
hypertrophy of the heart
• Fatty acid metabolism • Glypican 2 network • Cell adhesion-ECM remodeling
• Transport of glucose and other sugars, bile salts and organic
acids, metal ions and amine compounds
• Glycine cleavage • Collagen biosynthesis and modifying
enzymes
• P70S6K signaling • Pyrimidine ribonucleosides salvage
I
• Degradation of extracellular matrix
• Mitochondrial LC-Fatty acid beta-oxidation • Guidance cues and growth cone
motility
• Metabolism of O-linked glycosylation of
mucins
• Platelet homeostasis • Netrin signaling • Complement and coagulation cascades
• LDL oxidation in atherogenesis • Basal cell carcinoma • Interferon signaling
• MSP-RON signaling • Defensins • Cytoskeleton remodeling neuroﬁlaments
• Arf1 Pathway • Sweet taste signaling • HIF-1 alpha transcription factor network
• Lamivudine Pathway, Pharmacokinetics/Pharmacodynamics • Antiarrhythmic pathway • PAK pathway
• Acetaminphen Pathway, Pharmacokinetics • Non-integrin membrane-ECM interactions
• Nitric Oxide Stimulates Guanylate Cyclase • Dissolution of ﬁbrin clot
• AKT Signaling • All-trans-retinoic acid mediated apoptosis
• Immune Response-MIF-mediated glucocorticoid regulation • Formation of ﬁbrin clot (clotting cascade)
• Doxorubicin Pathway, Pharmacokinetics • Matrix metalloproteinases
• CREB Pathway • Legionellosis
• Axon Guidance • Validated transcriptional targets of AP1 family
members Fra1 and Fra2
• pERK Regulated gene expression • Rheumatoid arthritis
• ERK signaling
doi:10.1371/journal.pone.0152995.t001
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extended this observation to include human squamous carcinoma cell lines, SCC-25 and SCC-
61 treated with cisplatin (Fig 2), and an orthotopic mouse model of HNC. We found that AMP
peptide appeared to work synergistically with radiation to favorably impact the course of
tumor growth. In contrast animals given vehicle exhibited progressive cancer growth.
In addition to having anti-tumor activity, there was dramatic improvement in the develop-
ment and progression of OM in the irradiated head and neck tumor bearing animals. Fewer
animals treated with AMP peptide developed oral mucosal ulcers in addition to a significant
decrease in mucositis scores compared to mice given the vehicle. Further, the onset of mucosi-
tis was delayed in AMP peptide treated animals and the peak disease period was shorter (Fig
5). Taken together in this dual animal model of HNC and OM, AMP peptide can protect and
speed healing of the injured oral mucosa following radiation therapy, yet additively with radia-
tion inhibit tumor cell growth. As noted above, the stabilizing impact of AMP peptide on TJs
might, at least partially account for this observation. In addition the observation that AMP pep-
tide inhibition of TNF-α induced cleavage of caspase 3 in nontransformed HaCaT cells, but
not HNC SCC-25 cells might reflect its differential effect on apoptosis. Finally AMP-18 could
inhibit tumor growth by inducing cancer cell senescence [47, 48].
AMP-18 impacted the differential expression of a range of genes in SCC-61 cells compared
to SCC-AMP-naïve cells and compared to the effect of the peptide on normal HaCaT cells. The
most informative data associated with these genomic differences was associated with function
and, particularly, their attribution to specific pathways (Table 1). Consequently, the differential
gene expression evoked by AMP-18 between HaCaT and SCC cells was of interest. Not surpris-
ingly, given the phenotypic observations noted with AMP-18, its addition for 2 hours to SCC-
61 cells activated multiple pathways known to be associated with tumor behavior. Examples of
these pathways include fatty acid biosynthesis and metabolism [49], cell proliferation and inva-
siveness of squamous cell carcinomas of the head and neck [49], the Arf1 [50] and mTOR/
P70S6K pathways [51].
Interestingly, pathways associated with the extracellular matrix (ECM) were highly visible
among AMP-18 exposed cells. Given the importance of ECM in tumor invasiveness and its
specific relationship with epithelium, this finding may have importance in AMP-18’s ability to
modify tumor responsiveness, and is consistent with the report of Liu et al. [52] in which the
authors evaluated an integrated dataset of 4 public oral squamous cell carcinoma datasets and
found that alterations in ECM receptor pathways were the most common seen. It is not sur-
prising, therefore, that pathways associated with collagen biosynthesis and matrix metallopro-
teinases were among those highly ranked in our analysis. Taken together with the observations
of the potential of AMP-18 to impact the tumor environment, it could be that the peptide’s
effect of tumor behavior is more focused on invasiveness and local and systemic expansion
than on direct viability, such as PAK pathway mediated-cell motility.
Finally, the selenium pathway was prominently identified. Its significance in our model has
yet to be defined, but enhanced selenoprotein production might be associated with favorable
anti-tumor effects, as its depletion has been noted to have the opposite effect [53]. Alterna-
tively, given consistent reports of its ability to enhance tumor cell apoptosis [54], one might
hypothesize that AMP-18-mediated stimulation of the selenium pathway resulted in increased
levels of metabolites which inhibited observed tumor growth.
In summary, we have identified a novel agent that acts additively with radiation or chemo-
therapy to limit tumor cell growth while maintaining integrity of oral mucosal barrier function,
possibly through proliferative and anti-apoptotic effects in epithelial cells. The dual effects of
the peptide have yet to be fully defined, but the data presented here suggest its potential efficacy
as a new agent to treat patients with HNC who frequently develop mucositis.
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